Navidea Biopharmaceuticals, Inc.
NAVBDelisted Jan 16, 2024- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000810509
Navidea Biopharmaceuticals, Inc. was delisted on Jan 16, 2024; its insiders filed their last Form 4 on Dec 5, 2023; 24 institutions reported holding it in 13F filings for Q3 2023, worth $225.8K in total; no superinvestor held it.
Q3 2023 vs. Q2 2023
How the institutions holding Navidea Biopharmaceuticals, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 23 | 24 | +1 |
| Shares | 1.51M | 2.52M | +1.01M (+67.1%) |
| Value | $138.5K | $225.8K | +$87.3K (+63.0%) |
New holders (4)
Institutions that held Navidea Biopharmaceuticals, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Virtu Financial LLC | 333,069 | $30.0K | 0.00% |
| Warberg Asset Management LLC | 194,997 | $17.5K | 0.01% |
| Level Four Advisory Services, LLC | 55,555 | $4.98K | 0.00% |
| GWM Advisors LLC | 412 | $36 | 0.00% |
Sold out (3)
Institutions that held Navidea Biopharmaceuticals, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Susquehanna International Group, LLP | 125,866 | $11.6K |
| Cubist Systematic Strategies, LLC | 10,003 | $920 |
| Northwestern Mutual Wealth Management Co | 110 | $10 |